Abstract
Antibody formulations are described comprising a mixture of an anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.
Full Text
What is claimed is:
Antibody formulations are described comprising a mixture of an anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.
Timeline
Filed
03/17/2026Published
07/09/2026Granted
Not AvailableIPC Codes(8)
C07K 16/28:against receptors, cell surface antigens or cell surface determinants
A61K 9/00:Medicinal preparations characterised by special physical form
A61K 39/00:Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N 33/53)